Non-Alcoholic Steatohepatitis Pathogenesis: Role of Repair in Regulating the Disease Progression

被引:24
|
作者
Jung, Youngmi [1 ]
Diehl, Anna Mae [1 ]
机构
[1] Duke Univ, Div Gastroenterol, Durham, NC 27710 USA
关键词
Apoptosis; Liver regeneration; Fibrogenesis; Progenitors; Hedgehog; FATTY LIVER-DISEASE; IKK-BETA; HEDGEHOG; ACTIVATION; APOPTOSIS; VIABILITY; CELLS;
D O I
10.1159/000282092
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Increased hepatocyte apoptosis distinguishes non-alcoholic steatohepatitis (NASH) from non-alcoholic fatty liver disease (NAFLD). Therefore, we postulated that outcomes of NASH depended upon whether or not hepatic regenerative responses could keep pace with the increased rate of hepatocyte death. Methods: To investigate mechanisms that the liver deploys to compensate for increased hepatocyte apoptosis, we studied a transgenic mouse model in which hepatocyte vulnerability to apoptosis was increased due to disruption of NF-kappa B survival signaling. Results: We learned that hepatocyte death is coupled to the expansion of cell types that are involved in liver repair, including progenitors and myofibroblasts, and discovered that the outgrowth of these cell types occurs, at least in part, because dying hepatocytes produce Hedgehog morphogens that enhance the growth of progenitor and myofibroblast populations. The clinical significance of this discovery is supported by evidence that the degree of Hedgehog pathway activation also parallels the severity of liver fibrosis in patients with NASH, a disease in which hepatocyte apoptotic activity has been strongly linked to fibrosis progression. Conclusion: The data generated by studying a mouse model of chronic hepatocyte apoptosis, as well as NASH, a common human liver disease that is characterized by increased rates of hepatocyte apoptosis, are very similar. Both strongly support the concept that repair responses play an important role in controlling the outcomes of NASH. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:225 / 228
页数:4
相关论文
共 50 条
  • [1] Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis
    Wang, Qi
    Zhou, Haoming
    Bu, Qingfa
    Wei, Song
    Li, Lei
    Zhou, Jinren
    Zhou, Shun
    Su, Wantong
    Liu, Mu
    Liu, Zheng
    Wang, Mingming
    Lu, Ling
    JOURNAL OF HEPATOLOGY, 2022, 77 (02) : 312 - 325
  • [2] Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches
    Schuppan, Detlef
    Schattenberg, Jorn M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 68 - 76
  • [3] Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
    Baker, Susan S.
    Baker, Robert D.
    Liu, Wensheng
    Nowak, Norma J.
    Zhu, Lixin
    PLOS ONE, 2010, 5 (03): : A82 - A92
  • [4] MLK3 as a regulator of disease progression in Non-alcoholic steatohepatitis
    Jiang, Joy X.
    Toeroek, Natalie J.
    LIVER INTERNATIONAL, 2014, 34 (08) : 1131 - 1132
  • [5] Key molecular pathways in the progression of non-alcoholic steatohepatitis
    Tong, J.
    Guo, J-J
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (19) : 8515 - 8522
  • [6] The expression and secretion of vimentin in the progression of non-alcoholic steatohepatitis
    Lee, Su Jin
    Do Yoo, Jae
    Choi, Soo Young
    Kwon, Oh-Shin
    BMB REPORTS, 2014, 47 (08) : 457 - 462
  • [7] Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
    Zhu, Bo
    Chan, Siu-Lung
    Li, Jack
    Li, Kathryn
    Wu, Hao
    Cui, Kui
    Chen, Hong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [8] Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis
    Musso, Giovanni
    Gambino, Roberto
    Cassader, Maurizio
    PROGRESS IN LIPID RESEARCH, 2013, 52 (01) : 175 - 191
  • [9] Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
    Ibrahim, Samar H.
    Hirsova, Petra
    Gores, Gregory J.
    GUT, 2018, 67 (05) : 963 - +
  • [10] Role of microRNAs in Non-Alcoholic Steatohepatitis
    Cheung, Onpan
    Sanyal, Arun J.
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (17) : 1952 - 1957